首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITP |
| Uniprot No | Q9UKP3 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-347aa |
| 氨基酸序列 | MSLLCRNKGCGQHFDPNTNLPDSCCHHPGVPIFHDALKGWSCCRKRTVDFSEFLNIKGCTMGPHCAEKLPEAPQPEGPATSSSLQEQKPLNVIPKSAETLRRERPKSELPLKLLPLNISQALEMALEQKELDQEPGAGLDSLIRTGSSCQNPGCDAVYQGPESDATPCTYHPGAPRFHEGMKSWSCCGIQTLDFGAFLAQPGCRVGRHDWGKQLPASCRHDWHQTDSLVVVTVYGQIPLPAFNWVKASQTELHVHIVFDGNRVFQAQMKLWGVINVEQSSVFLMPSRVEISLVKADPGSWAQLEHPDALAKKARAGVVLEMDEEESDDSDDDLSWTEEEEEEEAMGE |
| 预测分子量 | 38,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITP(免疫性血小板减少症)重组蛋白的3篇示例参考文献(基于真实研究背景，文献名称和作者为示例性描述)：
---
1. **文献名称**：*"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy"*
**作者**：Kuter DJ, Rummel M, Boccia R 等
**摘要**：本研究评估了重组TPO受体激动剂romiplostim在慢性ITP患者中的长期(5年)疗效和安全性。结果显示，持续治疗可显著提高血小板计数，减少出血风险，且耐受性良好。
2. **文献名称**：*"Eltrombopag for the treatment of chronic immune thrombocytopenia: results from a phase III randomized trial"*
**作者**：Bussel JB, Provan D, Shamsi T 等
**摘要**：通过III期临床试验，验证了口服重组TPO受体激动剂eltrombopag治疗ITP的有效性。患者血小板水平显著提升，且药物安全性符合预期，为ITP提供了非注射治疗选择。
3. **文献名称**：*"Recombinant human thrombopoietin: mechanisms and clinical implications in immune thrombocytopenia"*
**作者**：Li J, Yang C, Xia Y 等
**摘要**：综述了重组人血小板生成素(rhTPO)的作用机制及其在ITP治疗中的应用，强调其通过刺激巨核细胞分化提升血小板生成，并与免疫调节疗法的协同潜力。
---
**备注**：
- Romiplostim和eltrombopag是已获批的ITP治疗药物，相关研究发表于《Blood》《Lancet》等期刊。
- 实际文献需通过PubMed或学术数据库检索，上述示例基于真实研究背景概括。
**Background of Recombinant Proteins in ITP**
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts due to immune-mediated destruction of platelets and impaired platelet production. Traditional treatments, such as corticosteroids, immunosuppressants, or splenectomy, often have limited efficacy or carry significant side effects. This unmet need has driven research into targeted therapies, including recombinant proteins, to address the underlying pathophysiology.
Recombinant protein technology emerged as a pivotal tool in developing biologics for ITP. Thrombopoietin (TPO), a key hormone regulating platelet production, became a focus. Early attempts using recombinant human TPO showed promise but were halted due to immunogenicity concerns. Later, second-generation TPO receptor agonists (TPO-RAs), such as romiplostim and eltrombopag, were engineered using recombinant DNA techniques. These agents mimic TPO’s effects, stimulating megakaryocyte proliferation and platelet production without eliciting strong immune responses.
Romiplostim, an Fc-peptide fusion protein, and eltrombopag, a small-molecule agonist, exemplify how recombinant strategies diversify therapeutic options. Their development leveraged structural biology insights to optimize receptor binding and pharmacokinetics. Clinical trials demonstrated efficacy in raising platelet counts and reducing bleeding risk, even in refractory ITP.
Beyond TPO-RAs, recombinant proteins like Fc-engineered antibodies (e.g., rozanolixizumab) targeting FcRn to reduce IgG autoantibodies are under exploration. These innovations highlight the shift toward precision medicine in ITP, aiming to balance efficacy with minimized systemic immunosuppression.
Overall, recombinant proteins have transformed ITP management by offering targeted, predictable, and tunable therapies. Ongoing research focuses on improving safety profiles, combination strategies, and personalized dosing, reinforcing their role as cornerstone treatments in hematologic autoimmunity.
×
